CA
NZ
UK
AU
IND
US
Harrow (Nasdaq: HROW) fell 7 per cent to $35.50 in after-hours trading on Tuesday after the ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million — a figure that, on the surface, understates the underlying commercial momentum by the amount of a specific and …
Exagen Inc. (Nasdaq: XGN) surged 35 per cent to close at $3.98 on Tuesday after the medical diagnostics company reported a first quarter that exceeded expectations on the metrics that matter most for a diagnosticsBusinessat this stage of its commercial development: volume, pricing, and …
Liquidia Corporation (Nasdaq: LQDA) delivered one of the most emphatic commercial readouts in the pulmonary hypertension space on Tuesday, sending its shares 25 per cent higher to close at $53.13 as investors digested a first-quarter performance that left little room for equivocation. YUTREPIA, the …
Actuate Therapeutics (Nasdaq: ACTU) closed 10 per cent lower at $2.98 on Tuesday, in what may rank as one of the more counterintuitive market reactions of the session. The company had just announced that the US Food and Drug Administration had cleared its Investigational …
Aditxt, Inc. (NASDAQ: ADTX) closed 8 per cent lower at $0.11 on Tuesday as shareholders absorbed the implications of a Nasdaq Staff Determination letter that brought the company to the edge of a potentially terminal regulatory cliff. The disclosure confirmed what the share price …
Shares in Ensysce Biosciences (Nasdaq: ENSC) closed 9 per cent higher at $0.38 on Tuesday, as the company placed itself at the centre of one of the most consequential debates in contemporary pharmacology: how to engineer effective pain relief without handing patients or recreational …
aTyr Pharma (Nasdaq: ATYR) slipped 9 per cent to $0.87 in after-hours trading on Tuesday after the clinical-stage biotherapeutics company disclosed a revised Phase 3 strategy for efzofitimod in pulmonary sarcoidosis — a revision prompted by feedback from the US Food and Drug Administration …
Liquidia Corporation (NASDAQ: LQDA) delivered one of the most emphatic commercial readouts in the pulmonary hypertension space on Tuesday, sending its shares soaring 23.29 per cent to $52.15 as investors digested a first-quarter performance that left little room for equivocation. YUTREPIA, the company's inhaled …
Shares in Ensysce Biosciences (NASDAQ: ENSC) edged lower on Tuesday, falling 3.08 per cent to $0.3394, even as the company placed itself at the centre of one of the most consequential debates in contemporary pharmacology: how to engineer effective pain relief without handing patients …
Zai Lab Limited (NASDAQ: ZLAB) added 5.65 per cent on Tuesday to close at $19.65, lifted by news that the FDA has extended a second Fast Track Designation to zocilurtatug pelitecan — known within the oncology community as zoci — for the treatment of …
Please wait processing your request...